文献速递心力衰竭与心肌病

达格列净对射血分数轻度降低或保留心衰患者的长期获益估计

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2022-08-27

该研究为DELIVER试验的预设分析,采用非参数年龄方法外推达格列净长期治疗的无事件生存获益。共纳入6263例有症状、左室射血分数>40%的心衰患者,65岁患者无主要终点事件生存期达格列净组较安慰剂组延长2.3年(95%CI 0.9-3.8,P=0.002)。

要点

  • 65岁患者无事件生存期达格列净组12.1年 vs 安慰剂组9.7年,绝对延长2.3年。
  • 获益在55岁至75岁间随年龄增长而减小,55岁延长2.0年,75岁延长1.2年。
  • 全部14个预设亚组中达格列净组无事件生存期均优于安慰剂组。

核心结论

  • 达格列净预计可使中年及老年射血分数轻度降低或保留的心衰患者无事件生存期延长2.0至2.5年。

研究设计与样本

  • DELIVER试验的预设分析,应用基于年龄的非参数方法外推达格列净长期治疗的无事件生存获益。
  • 共纳入6263例有症状心衰、左室射血分数>40%、利钠肽升高且存在结构性心脏病的患者。

主要发现

  • 65岁患者无主要终点事件平均生存期:达格列净组12.1年(95%CI 11.0-13.2),安慰剂组9.7年(95%CI 8.8-10.7)。
  • 65岁患者无事件生存获益为2.3年(95%CI 0.9-3.8,P=0.002)。
  • 55岁患者获益2.0年(95%CI -0.6至4.6),75岁患者获益1.2年(95%CI -0.1至2.4)。
  • 全部14个亚组中达格列净组无事件生存期均大于安慰剂组。

临床怎么用

  • 对射血分数轻度降低或保留的心衰患者,可考虑长期使用达格列净以延长无事件生存期。
  • 与患者沟通预期获益时可参考年龄相关的生存延长时间估计。

局限性

  • 获益估计基于生存曲线外推方法,非直接观察到的长期随访数据。
  • 部分年龄亚组的获益置信区间包含0,不确定性较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent guidelines support consideration of sodium-glucose cotransporter-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ejection fraction. Patients and clinicians may be interested in the expected lifetime benefits of sodium-glucose cotransporter-2 inhibitors in this population. OBJECTIVES: This study aimed to estimate event-free survival gains from long-term use of dapagliflozin in patients with HF with mildly reduced or preserved ejection fraction overall and in clinically relevant subgroups. METHODS: In this prespecified analysis of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), we applied validated nonparametric age-based methods to extrapolate potential gains in survival free from the primary endpoint (cardiovascular death or worsening HF event) from long-term use of dapagliflozin. Eligible participants had symptomatic HF, left ventricular ejection fraction >40%, elevated natriuretic peptide levels, and structural heart disease. For every year between the ages of 55 and 85 years, we estimated event-free survival using age at randomization rather than time from randomization as the time horizon. Residual lifespan free from a primary endpoint was estimated based on area under the survival curve in each arm. RESULTS: Among 6,263 participants, mean survival free from the primary endpoint for a 65-year-old participant was 12.1 years (95% CI: 11.0-13.2 years) with dapagliflozin and 9.7 years (95% CI: 8.8-10.7 years) with placebo, representing a 2.3-year (95% CI: 0.9-3.8 years) event-free survival gain (P = 0.002). Treatment gains in survival free from the primary endpoint ranged from 2.0 years (95% CI: -0.6 to 4.6 years) in a 55-year-old to 1.2 years (95% CI: -0.1 to 2.4 years) in a 75-year-old patient. Mean event-free survival was greater with dapagliflozin than with placebo across all 14 subgroups. CONCLUSIONS: Treatment with dapagliflozin is projected to extend event-free survival by up to 2.0 to 2.5 years among middle-aged and older individuals with HF with mildly reduced or preserved ejection fraction. (DELIVER [Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure]; NCT03619213).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Vaduganathan, Claggett, Jhund, et al. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2022. PMID: 36041669. doi:10.1016/j.jacc.2022.08.745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。